$108.4 M

LTRN Mkt cap, 12-Nov-2021
Lantern Pharma Net income (Q1, 2021)-2.5 M
Lantern Pharma Cash, 31-Mar-202181.4 M
Get notified regarding key financial metrics and revenue changes at Lantern PharmaLearn more
Banner background

Lantern Pharma Income Statement

Annual

USDFY, 2018FY, 2019FY, 2020

R&D expense

572.1k953.2k

General and administrative expense

1.2m1.5m3.7m

Operating expense total

1.7m2.4m3.7m

Net Income

(1.7m)(2.4m)(5.9m)

EPS

(0.9)(1.2)

Quarterly

USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

R&D expense

186.0k361.3k228.4k137.1k157.0k600.8k1.3m

General and administrative expense

267.9k268.1k441.3k340.2k676.4k1.1m1.2m

Operating expense total

454.0k629.4k669.7k477.3k833.4k1.7m2.5m

Net Income

(454.0k)(629.4k)(669.7k)(477.3k)(833.4k)(1.7m)(2.5m)

EPS

(0.4)(0.3)(0.3)(0.4)(0.3)(0.3)

Lantern Pharma Balance Sheet

Annual

USDFY, 2018FY, 2019FY, 2020

Cash

445.2k1.2m19.2m

Prepaid Expenses

788.01.0m

Current Assets

445.2k1.2m20.2m

PP&E

4.7k8.8k21.5k

Total Assets

449.8k1.4m20.4m

Accounts Payable

116.6k489.3k108.5k

Current Liabilities

651.6k489.3k552.3k

Total Liabilities

651.6k489.3k660.8k

Common Stock

198.0198.0622.0

Preferred Stock

129.0244.0

Additional Paid-in Capital

4.1m7.7m32.4m

Retained Earnings

(4.3m)(6.8m)(12.7m)

Total Equity

(201.8k)943.3k19.7m

Financial Leverage

-2.2 x1.5 x1 x

Quarterly

USDQ1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

634.2k23.8m20.8m81.4m

Prepaid Expenses

132.1k70.8k1.7m1.1m

Current Assets

766.4k25.6m22.5m82.5m

PP&E

8.2k15.4k17.6k20.2k

Total Assets

1.0m25.6m22.5m82.5m

Accounts Payable

448.3k468.0k814.6k108.5k

Short-term debt

53.3k102.8k

Current Liabilities

501.5k2.3m814.6k664.5k

Long-term debt

108.5k108.5k

Total Debt

53.3k211.3k108.5k

Total Liabilities

501.5k2.4m923.1k773.0k

Common Stock

117.0622.0622.01.1k

Preferred Stock

140.0

Additional Paid-in Capital

7.8m31.3m31.3m96.8m

Retained Earnings

(7.2m)(8.1m)(9.8m)(15.1m)

Total Equity

536.5k23.2m21.6m81.7m

Debt to Equity Ratio

0.1 x0 x0 x

Debt to Assets Ratio

0.1 x0 x0 x

Financial Leverage

1.9 x1.1 x1 x1 x

Lantern Pharma Cash Flow

Annual

USDFY, 2018FY, 2019FY, 2020

Net Income

(1.7m)(2.4m)(5.9m)

Depreciation and Amortization

(2.5k)1.6k3.4k

Accounts Payable

70.2k372.7k(169.0k)

Cash From Operating Activities

(1.3m)(2.1m)(5.7m)

Purchases of PP&E

5.3k(5.7k)

Cash From Investing Activities

5.3k(5.7k)(16.1k)

Cash From Financing Activities

535.0k2.9m23.7m

Net Change in Cash

(731.2k)786.9k18.0m

Quarterly

USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(454.0k)(1.1m)(1.8m)(477.3k)(1.3m)(3.0m)(2.5m)

Depreciation and Amortization

315.0629.01.1k536.01.2k2.3k1.3k

Accounts Payable

57.5k224.4k304.5k(41.0k)(61.7k)431.0k164.1k

Cash From Operating Activities

(425.6k)(869.1k)(1.4m)(703.0k)(1.2m)(4.1m)(2.1m)

Purchases of PP&E

(5.7k)(7.8k)(11.1k)

Cash From Investing Activities

(5.7k)(7.8k)(11.1k)

Long-term Borrowings

(13.0k)(66.2k)(169.0k)

Cash From Financing Activities

1.9m1.9m2.9m105.3k23.8m23.7m64.3m

Net Change in Cash

1.4m980.9k1.5m(597.8k)22.6m19.6m62.1m

Lantern Pharma Ratios

USDFY, 2018

Financial Leverage

-2.2 x